For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > REGULATORY
REGULATORY
- PAFSC 1st Committee Recommends Irribow Use in Females
May 1, 2015
- Submission of CDISC-Based Clinical Data Required from October 2016: Notification
April 30, 2015
- Thrombocytopenia Added to Clinically Significant ADR List for Januvia, Glactiv: Safety Bulletin
April 30, 2015
- Scrutinize Purpose of Price Maintenance Premium for New Drugs: MOF
April 28, 2015
- MOF Presses for 80% Generic Share Target by FY2017
April 28, 2015
- Number of Topics Discussed by PAFSC Second Committee Exceeds that of First Committee for 1st Time in 10 Years: Jiho Tally
April 28, 2015
- Patient-Initiated Mixed Care Used Only When Compassionate Access Can’t Be Applied: Minister
April 28, 2015
- PAFSC Second Committee Backs Approval of Add’l Indication for PegIntron
April 27, 2015
- AMED, JPMA Discussing Joint Use of Compounds, with Policy Announcement Expected in Early June: Dr Suematsu of AMED
April 27, 2015
- MHLW Looking into Drug Maker Payments to PAFSC Members: Shiozaki
April 24, 2015
- LDP Weighs Clinical Development Infrastructure Utilizing Patient Registry
April 24, 2015
- Council on Unapproved Drugs to Issue Development Requests Immediately In Cases of Unanimous Approval by Working Groups
April 24, 2015
- MHLW Orders Revision of Package Inserts for Plavix
April 24, 2015
- Polyethylene Glycol Has Great Unmet Medical Need: Panel
April 23, 2015
- MHLW Official Jo Hints at Possible Move-Up of Generic Roadmap
April 23, 2015
- Find Solid Candidates from Early Development Stage: MHLW’s Mori
April 23, 2015
- Ease Post-Marketing Burdens for Intractable Disease Treatments: JPMA Exec
April 22, 2015
- AMED Chief Envisages Tapping Private Funds to Fuel R&D
April 22, 2015
- Editor’s Pick: Five Healthcare News Headlines for April 6 - 19
April 20, 2015
- Govt Checks on Progress of Healthcare R&D Promotion Plan
April 20, 2015
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…